More: 30th Annual San Antonio Breast Cancer Symposium (SABCS)

SABCS 2007: Adjuvant Treatment of Breast Cancer CME

December 13 - 16, 2007, San Antonio, Texas

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium.

Release Date: January 31, 2008; Valid for credit through January 31, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

  1. Adjuvant Therapy for HER2-Normal Early-Stage Breast CancerHeather McArthur, MDClifford Hudis, MD
  2. Endocrine Therapy: Highlights From SABCS 2007Harold J. Burstein, MD, PhD
  3. What's New in HER2-Targeted Therapy for Breast Cancer?Susanne Briest, MDAntonio C. Wolff, MD

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the San Antonio Breast Cancer Symposium. These materials and the related activity are not sanctioned by the San Antonio Breast Cancer Symposium or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Susan G. Komen
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Evaluate clinical trial data on the long-term use of endocrine therapy in the adjuvant setting in patients with early-stage breast cancer
  2. Describe the impact of aromatase inhibition therapy in patients with breast cancer
  3. Evaluate the relationship between HER2 testing and the efficacy of adjuvant trastuzumab therapy
  4. Discuss novel strategies for overcoming HER2 resistance in patients with HER2-positive breast cancer
  5. Explain the role of taxanes in the adjuvant chemotherapy strategy in patients with HER2-normal early-stage breast cancer
  6. Discuss the feasibility, safety, and efficacy of adjuvant therapy for older patients with breast cancer
Authors and Disclosures

Heather L. McArthur, MD
Disclosure: Heather L. McArthur, MD, has disclosed that she has received grants for educational activities from Amgen, Genentech, and GlaxoSmithKline.


Clifford A. Hudis, MD
Disclosure: Clifford A. Hudis, MD, has disclosed that he owns stock in Genomic Health and has received grants for clinical research from AstraZeneca, Genentech, and Kosan Biosciences. Dr. Hudis has also disclosed that he has served as an advisor or consultant to Amgen, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Novartis, Pfizer, and sanofi-aventis.


Harold J. Burstein, MD, PhD
Disclosure: Harold J. Burstein, MD, PhD, has disclosed no relevant financial relationships.


Susanne Briest, MD
Disclosure: Susanne Briest, MD, has disclosed no relevant financial relationships.


Antonio C. Wolff, MD
Disclosure: Antonio C. Wolff, MD, has disclosed that he has received grants for clinical research from Roche.


Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships.


Jill W. Chamberlain
Disclosure: Jill W. Chamberlain has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.